Entyvio
(Vedolizumab)
Provider Summary
Primary Uses
Moderate-to-severe ulcerative colitis and Crohn’s disease in adults (and other age groups per label), per payer criteria.
Mechanism of action
Integrin receptor antagonist (anti‑α4β7) with gut-selective mechanism that reduces lymphocyte trafficking to GI tract.
Pre-treatment / baseline requirements
Screen for infection; baseline CBC/CMP often requested; review history of PML symptoms (very rare with vedolizumab); immunizations per clinician.
Common side effects
Headache, arthralgia, nausea, fever, upper respiratory infection.
Serious adverse effects / key risks
Serious infections; hypersensitivity/infusion reactions; liver injury (uncommon).
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Moderate-to-severe ulcerative colitis and Crohn’s disease in adults (and other age groups)
How it works
Blocks immune-cell trafficking (gut-selective for some conditions).
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Headache, arthralgia, nausea, fever, upper respiratory infection.
Get urgent help for
Serious infections; hypersensitivity/infusion reactions; liver injury.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.